Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 5
Submit an article Journal homepage
167
Views
23
CrossRef citations to date
0
Altmetric
Review

Protein kinase C isozymes as potential therapeutic targets in immune disorders

Matthew R Lee Senior Scientist Amgen, Inc., Molecular Structure, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA
,
Wei Duan Associate Professor Deakin University, School of Medicine, Waurn Ponds, Victoria 3217, Australia
&
Seng-Lai Tan Principal Scientist Amgen, Inc., Hematology and Oncology Research, 1201 Amgen Court West, Seattle, WA 98119, USA +1 206 265 8866; +1 206 217 0494; [email protected]
Pages 535-552 | Published online: 15 Apr 2008

Bibliography

  • Nishizuka Y and Kikkawa U. Early studies of protein kinase C: a historical perspective. Methods Mol Biol 2003;233:9-18
  • Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci 2004;117:131-2
  • Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-64
  • Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007;7:281-94
  • Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006;235:1-10
  • Rhee JS, Betz A, Pyott S, et al. β phorbol ester- and diacylglycerol-induced augmentation of transmitter release is mediated by Munc13s and not by PKCs. Cell 2002;108:121-33
  • Jaken S, Parker PJ. Protein kinase C binding partners. Bioessays 2000;22:245-54
  • Leitges M, Schmedt C, Guinamard R, et al. Immunodeficiency in protein kinase cβ-deficient mice. Science 1996;273:788-91
  • Su TT, Guo B, Kawakami Y, et al. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002;3:780-6
  • Saijo K, Mecklenbrauker I, Santana A, et al. Protein kinase C βcontrols nuclear factor κB activation in B cells through selective regulation of the IκB kinase α. J Exp Med 2002;195:1647-52
  • Martin P, Duran A, Minguet S, et al. Role of ζ PKC in B-cell signaling and function. EMBO J 2002;21:4049-57
  • Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005;202:1363-74
  • Duran A, Diaz-Meco MT, Moscat J. Essential role of RelA Ser311 phosphorylation by ζPKC in NF-κB transcriptional activation. EMBO J 2003;22:3910-8
  • Savkovic SD, Koutsouris A, Hecht G. PKCζ participates in activation of inflammatory response induced by enteropathogenic E. coli. Am J Physiol Cell Physiol 2003;285:C512-21
  • Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cδ. Nature 2002;416:865-9
  • Mecklenbrauker I, Saijo K, Zheng NY, et al. Protein kinase C controls self-antigen-induced B-cell tolerance. Nature 2002;416:860-5
  • Shulga-Morskaya S, Dobles M, Walsh ME, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004;173:2331-41
  • Stohl W, Xu D, Kim DS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005;52:2080-91
  • Mecklenbrauker I, Kalled SL, Leitges M, et al. Regulation of B-cell survival by BAFF-dependent PKCδ-mediated nuclear signalling. Nature 2004;431:456-61
  • Patke A, Mecklenbrauker I, Erdjument-Bromage H, et al. BAFF controls B cell metabolic fitness through a PKCβ- and Akt-dependent mechanism. J Exp Med 2004;203:2551-62
  • Svensson L, Jirhoth J, Holmdahl R, et al. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol 1998;111:521-6
  • Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice. Am J Pathol 2003;163:1827-37
  • Nandakumar KS, Andren M, Martinsson P, et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcγRIIB. Eur J Immunol 2003;33:2269-77
  • Nandakumar KS, Backlund J, Vestberg M, et al. Collagen type (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells. Arthritis Res Ther 2004;6:R544-50
  • Edwards JC, Leandro MJ, Cambridge G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun 2005;8:175-92
  • Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58-61
  • Uckun FM, Tibbles H, Venkatachalam T, et al. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13). Arzneimittelforschung 2007;57:31-46
  • Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74
  • Venkataraman C, Chen XC, Na S, et al. Selective role of PKCβ enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking. Immunol Lett 2006;105:83-9
  • Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007;16:1693-707
  • Monks CR, Kupfer H, Tamir I, et al. Selective modulation of protein kinase C-θ during T-cell activation. Nature 1997;385:83-6
  • Bauer B, Krumbock N, Ghaffari-Tabrizi N, et al. T cell expressed PKCθdemonstrates cell-type selective function. Eur J Immunol 2000;30:3645-54
  • Monks CR, Freiberg BA, Kupfer H, et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998;395:82-6
  • Bi K, Tanaka Y, Coudronniere N, et al. Antigen-induced translocation of PKC-θ to membrane rafts is required for T cell activation. Nat Immunol 2001;2:556-63
  • Liu Y, Witte S, Liu YC, et al.:Regulation of protein kinase Cθ function during T cell activation by Lck-mediated tyrosine phosphorylation. J Biol Chem 2000;275:3603-9
  • Villalba M, Bi K, Hu J, et al. Translocation of PKCθ in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C. J Cell Biol 2002;157:253-63
  • Sun Z, Arendt CW, Ellmeier W, et al. PKC-θ is required for TCR-induced NF-B activation in mature but not immature T lymphocytes. Nature 2000;404:402-7
  • Pfeifhofer C, Kofler K, Gruber T, et al. Protein kinase Cθ affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003;197:1525-35
  • Gaide O, Favier B, Legler DF, et al. CARMA1 is a critical lipid raft-associated regulator of TCR-induced NF-κB activation. Nat Immunol 2002;3:836-43
  • Wang D, You Y, Case SM, et al. A requirement for CARMA1 in TCR-induced NF-κB activation. Nat Immunol 2002;3:830-5
  • Herndon TM, Shan XC, Tsokos GC, et al. ZAP-70 and SLP-76 regulate protein kinase C-θ and NF-κB activation in response to engagement of CD3 and CD28. J Immunol 2001;166:5654-64
  • Li Y, Hu J, Vita R, et al. SPAK kinase is a substrate and target of PKCθin T-cell receptor-induced AP-1 activation pathway. EMBO J 2004;23:1112-22
  • Manicassamy S, Sadim M, Ye RD, et al. Differential roles of PKC-θ in the regulation of intracellular calcium concentration in primary T cells. J Mol Biol 2006;355:347-59
  • Altman A, Kaminski S, Busuttil V, et al. Positive feedback regulation of PLCγ1/Ca(2+) signaling by PKCθ in restimulated T cells via a Tec kinase-dependent pathway. Eur J Immunol 2004;34:2001-11
  • Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell 2002;10:1269-81
  • Anton IM, de la Fuente MA, Sims TN, et al. WIP deficiency reveals a differential role for WIP and the actin cytoskeleton in T and B cell activation. Immunity 2002;16:193-204
  • Salek-Ardakani S, So T, Halteman BS, et al. Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase Cθ. J Immunol 2004;173:6440-7
  • Marsland BJ, Soos TJ, Späth G, et al. Protein kinase C θ is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med 2004;200:181-9
  • Salek-Ardakani S, So T, Halteman BS, et al. Protein kinase Cθ controls TH1 cells in experimental autoimmune encephalomyelitis. J Immunol 2005;175:7635-41
  • Tan SL, Zhao J, Bi C, et al. Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase Cθ-deficient mice. J Immunol 2006;176:2872-9
  • Healy AM, Izmailova E, Fitzgerald M, et al. PKC-θ-deficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol 2006;177:1886-93
  • Nagahama K Ogawa A, Shirane K, et al. Protein kinase C θ plays a fundamental role in different types of chronic colitis. Gastroenterology 2008;134;459-69
  • Berg-Brown NN, Gronski MA, Jones RG, et al. PKC signals activation versus tolerance in vivo. J Exp Med 2004;199:743-52
  • Barouch-Bentov R, Lemmens EE, Hu J, et al. Protein kinase C-θ is an early survival factor required for differentiation of effector CD8+ T cells. J Immunol 2005;175:5126-34
  • Schmidt-Supprian M, Tian J, Grant EP, et al. Differential dependence of CD4+ CD25+ regulatory and natural killer-like T cells on signals leading to NF-κB activation. Proc Natl Acad Sci USA 2004;101:4566-71
  • Marsland BJ, Nembrini C, Schmitz N, et al. Innate signals compensate for the absence of PKC during in vivo CD8+ T cell effector and memory responses. Proc Natl Acad Sci USA 2005;102:14374-9
  • Giannoni F, Lyon AB, Wareing MD, et al. Protein kinase Cα is not essential for T-cell-mediated clearance of murine gammaherpesvirus 68. J Virol 2005;79:6808-13
  • Pfeifhofer C, Gruber T, Letschka T, et al. Defective IgG2a/2b class switching in PKC α-/- mice. 2006;176:6004-11
  • Trushin SA, Pennington KN, Carmona EM, et al. Protein kinase Cα acts upstream of PKCθ to activate IκB kinase and NF-κB in T lymphocytes. Mol Cell Biol 2003;23:7068-81
  • Martin P, Villares R, Rodriguez-Mascarenhas S, et al. Control of T helper 2 cell function and allergic airway inflammation by PKCζ. Proc Natl Acad Sci USA 2005;102:9866-71
  • Gruber T, Fresser F, Jenny M, et al. PKCθ cooperates with atypical PKCζ and PKCι in NF-κB transactivation of T lymphocytes. Mol Immunol 2008;45:117-26
  • Castrillo A, Pennington DJ, Otto F, et al. Protein kinase Cϵ is required for macrophage activation and defense against bacterial infection. J Exp Med 2001;194:1231-42
  • Aksoy E, Amraoui Z, Goriely S, et al. Critical role of protein kinase C ϵ for lipopolysaccharide-induced IL-12 synthesis in monocyte-derived dendritic cells. Eur J Immunol 2002;32:3040-9
  • McGettrick AF, Brint EK, Palsson-McDermott EM, et al. Trif-related adaptor molecule is phosphorylated by PKCϵ during Toll-like receptor 4 signaling. Proc Natl Acad Sci USA 2006;103:9196-201
  • Nechushtan H, Leitges M, Cohen C, et al. Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase Cβ. Blood 2000;95:1752-7
  • Leitges M, Gimborn K, Elis W, et al. Protein kinase C-δ is a negative regulator of antigen-induced mast cell degranulation. Mol Cell Biol 2002;22:3970-80
  • Kawakami Y, Kitaura J, Yao L, et al. A Ras activation pathway dependent on Syk phosphorylation of protein kinase C. Proc Natl Acad Sci USA 2003;100:9470-5
  • Germano P, Gomez J, Kazanietz MG, et al. Phosphorylation of the γchain of the high affinity receptor for immunoglobulin E by receptor-associated protein kinase C-δ. J Biol Chem 1994;269:23102-7
  • Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther 2007; published online 28 Jun 2007, doi:10.1016/j.pupt.2007.06.002
  • Nixon JS, Bishop J, Bradshaw D, et al. Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity. Drugs Exp Clin Res 1991;17:389-93
  • Mulqueen MJ, Bradshaw D, Davis PD, et al. Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Agents Actions 1992;37:85-9
  • Birchall AM, Bishop J, Bradshaw D, et al. Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. J Pharmacol Exp Ther 1994;268:922-9
  • Jacobson PB, Kuchera SL, Metz A, et al. Anti-inflammatory properties of Gö6850: a selective inhibitor of protein kinase C. J Pharmacol Exp Ther 1995;275:995-1002
  • Farese RV, Sajan MP, Yang H, et al. Muscle-specific knockout of PKC-λ impairs glucose transport and induces metabolic and diabetic syndromes. J Clin Invest 2007;117:2289-301
  • Kim JK, Fillmore JJ, Sunshine MJ, et al. PKC-θ knockout mice are protected from fat-induced insulin resistance. J Clin Invest 2004;114:823-7
  • Gray S, Idris I, Davis KR, Donnelly R. Increased skeletal muscle expression of PKC-θ but not PKC-α mRNA in type 2 diabetes: inverse relationship with in-vivo insulin sensitivity. Eur J Clin Invest 2003;33:983-7
  • Gao Z, Wang Z, Zhang X, et al. Inactivation of PKCθ leads to increased susceptibility to obesity and dietary insulin resistance in mice. Am J Physiol Endocrinol Metab 2007;292:E84-91
  • Serra C, Federici M, Buongiorno A, et al. Transgenic mice with dominant negative PKC-theta in skeletal muscle: a new model of insulin resistance and obesity. J Cell Physiol 2003;196:89-97
  • Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep 2002;4:37-46
  • Vlahos CJ, McDowell SA, Clerk A. Kinases as therapeutic targets for heart failure. Nat Rev Drug Discov 2003;2:99-113
  • Wagner J. NVP-AEB071: oral and specific inhibitor of t cell activation for the prevention of graft rejection and the treatment of autoimmune diseases. discovery and selection of successful drug candidates. Fall meeting of the Swiss Chemical Society 2007 Ecole Polytechnique Fédérale de Lausanne Wednesday, 2007 September 12. Available from: http://scs-fallmeeting.epfl.ch/Files/abstracts/57.pdf
  • Xu RX, Pawelcyzk T, Brown SC. NMR structure of a protein kinase C-γ phorbol-binding domain and study of protein-lipid micelle interactions. Biochememistry 1997;36:10709-17
  • Benes CH, Wu N, Elia AEH, et al. The C2 domain of PKCδ is a phosphotyrosine binding domain. Cell 2005;121:271-80
  • Ochoa WF, Garcia-Garcia J, Corbalan-Garcia IFS, et al. Structure of the C2 domain from novel protein kinase Cϵ. A membrane binding model for Ca (2+)-independent C2 domains. J Mol Biol 2001;311:837-49
  • Brandman R, Disatnik M-H, Churchill E, et al. Peptides derived from the C2 domain of protein kinase Cϵ(ϵPKC) modulate ϵPKC activity and identify potential protein–protein interaction surfaces. J Biol Chem 2007;282:4113-23
  • Li H. Protein kinase C: novel isozyme-selective peptide inhibitors. Expert Opin Ther Patents 2006;16:1183-7
  • KAI Pharmaceuticals, Inc. KAI Pharmaceuticals presents encouraging phase 1/2 results of a novel treatment for heart attack (Press release). KAI Pharmaceuticals, Inc., South San Francisco, USA; 2007
  • Zhu Y, Lim WG, Tan BJ, et al. Identification of an integral plasma membrane pool of protein kinase C in mammalian tissues and cells. Cell Signal 2005;17:1125-36
  • Zhu Y, Smith D, Verma C, et al. The very C-terminus of protein kinase Cϵ is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1. Cell Signal 2006;18:807-18
  • Yeong SS, Zhu Y, Smith D, et al. The last 10 amino acid residues beyond the hydrophobic motif are critical for the catalytic competence and function of protein kinase Cα. J Biol Chem 2006;281:30768-81
  • Xu ZB, Chaudhary D, Olland S, et al. Catalytic domain crystal structure of protein kinase C-θ. J Biol Chem 2004;279:50401-9
  • Available from: www.genecards.org
  • Available from: www.ihop-net.org
  • Albert R, Bigaud M, Cottens S, et al. First demonstration that novel, potent and selective protein kinase C inhibitors prevent allograft rejection after oral administration. 11th Congress of the European Society for Organ Transplantation held in conjunction with the 13th European Transplant Coordinators Organization; 2003 September 20 – 24; Venice, Italy
  • Kelland L. Discontinued drugs in 2005: oncology drugs. Expert Opin Investig Drugs 2006;15:1309-18
  • Rosenthal MA, Oratz R, Liebes L, et al. Phase I study of bryostatin-1 (NSC 339555) and cisplatin in advanced malignancies. 35th Annual Meeting of the American Society of Clinical Oncology; Atlanta Georgia 1999 May 15 – 18;18:227
  • Bedikian AY, Plager C, Stewart JR, et al. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 2001;11:183-8
  • Blackhall FH, Ranson M, Radford JA, et al. A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. Br J Cancer 2001;84:465-9
  • Tozer RG, Burdette-Radoux S, Berlanger K, et al. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 2002;20:407-12
  • Camidge DR, Gail Eckhardt S, Gore L, et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008;19:77-84
  • Rademaker-Lakhai JM, Beerepoot LV, Mehra N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007;13:4474-81
  • Butowski N, Lamborn K, Chang S, et al. Phase I/pharmacokinetic study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics San Francisco, USA 22 – 26 Oct 2007; 75
  • McDonald AC, Propper D, King D, et al. Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase C. 33rd Annual Meeting of the American Society of Clinical Oncology Denver, Colorado, USA 17 – 20 May 1997; 212
  • Virchis AE, Ganeshaguru K, Prentice HG, et al. Results of an exploratory phase II study on a protein kinase C inhibitor in low grade lymphoproliferative disorders. Br J Haematol 1998;102:192
  • Millward MJ, House C, Bowtell D, et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer 2006;95:829-34
  • Skljarevski V, Bai S, Amador AG, et al. Ruboxistaurin mesylate improves positive sensory symptoms and neurological signs of diabetic peripheral neuropathy. Neurology 2004;62(Suppl 5):192-3
  • Milton R, Aiello L, Davis M, et al. Initial results of the protein kinase C b inhibitor diabetic retinopathy study (PKC-DRS). Diabetes 2003;52(Suppl 1):127
  • Aiello LP, Davis MD, Milton RC, et al. Initial results of the protein kinase C beta inhibitor Diabetic Macular Edema Study (PKC-DMES). Diabetologia 2003;46(Suppl 2):42
  • Schaar D. A phase I clinical trial of 12-O-etradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol 2006;57:789-95
  • Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity 7-hydroxystaurosporine (UCN01) a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7
  • Sawsville, EA. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33
  • Dees, EC. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 2005;11:664-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.